




Life Sciences Financing Summary Europe

June 2016

In March 2016, we saw a sharp increase in total financing value (EUR 205m from EUR 125m in February 2016). The aggregate value was due to 12 rounds and an average deal size of EUR 18m per round. In April 2016, the aggregate financing value was considerably less, dropping to EUR 147m. A year on year comparison for March and April, however, shows that total financing values have increased for both months with EUR 94m for March 2015 and EUR 129m for April 2015.

The largest private financing round for European Therapeutics & Diagnostics companies in March and April 2016 was the EUR 46m raised in March by Aprea AB, one of the largest private financings ever for a Scandinavian biotech company. Continue reading below to learn more about the financing highlights of March and April 2016 in the European Life Science industry.

Europe - Biotech Therapeutic Financing Rounds



Source: Biotechgate.com

*The graph contains only financing rounds of private & independent biotech therapeutic and diagnostic companies. Financing amounts and number of rounds from previous months may alter as new information on financing rounds is received and/or new tranches to existing financing rounds are added.



Selected financing highlights: companies raising funds

April 2016

MedDay Secures EUR 34m New Funding

Paris, France,- MedDay, a biotechnology company focused on the treatment of nervous system disorders, announced on the 8th of April 2016 that it has raised EUR 34m of new capital in a Series B financing round. Edmond de Rothschild Investment Partners (EDRIP) led the new investment round alongside existing investors Sofinnova Partners and InnoBio (Bpifrance). Large Venture (Bpifrance) also participated in the operation. The new funds will enable MedDay to conduct a confirmatory phase-3 study in United States "SPI2", following the successful phase-3 MS-SPI study in 2015 in progressive multiple sclerosis, with its wholly-owned lead candidate, MD1003. The funds will also accelerate pre-launch activities of MD1003 in Europe, where the drug is currently being supplied by MedDay on a named patient basis, the development of other pipeline candidates as well as the advancement of a research platform aimed at identifying new metabolic targets in neurological diseases.

(Source: press release)

March 2016

Apra Closes EUR 46m Series B Financing

Stockholm, Sweden- Apra AB, a clinical-stage biotechnology company developing novel anticancer therapies targeting the tumor suppressor protein p53, announced on the 9th of March 2016 that it has completed a Series B financing round, raising EUR 46m. The international syndicate was co-led by Versant Ventures and 5AM Ventures, with participation by Sectoral Asset Management. HealthCap acted as the local lead investor. Apra's main shareholder is KDev Investments AB, an investment vehicle owned by Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital Ltd. The funds will be used to advance the clinical development of lead program APR-246, a first-in-class anticancer compound reactivating the tumor suppressor protein p53.

(Source: press release)



Selected financing highlights – investors in March, April 2016


The following investors have made investments into European Life Science companies during March and April 2016:

- 5AM Ventures Aurum Ventures
- Canaan Partners
- Boehringer Ingelheim
- Edmond de Rothschild Investment Partners (EDRIP)
- Glide Healthcare
- HealthCap
- INKEF Capital
- InnoBio (Bpifrance)
- Kurma Partners
- New Leaf Venture Partners.
- Sectoral Asset Management
- Sofinnova Partners
- Versant Ventures
- Wellington Partners

Quarterly Biotech Equity Financing Breakdown by Lead Product Development Phase (Therapeutics & Diagnostics)

With the last quarter of 2015 ending with no financings for companies with projects in Phase III, we saw a different scenario in Q1 2016. As with Q4 2015, we saw the majority of financing going into Phase II. However, there was a sharp drawdown in Phase I financing with only 14% of the total amount for Q1 2016. Also, as compared with the previous quarter, there was a larger proportion in Phase III financing (14% of total) and Preclinical (29% of total).

Financing by Lead Product Development Phase



Source: Biotechgate.com

*The graph above shows the proportion of financing rounds by lead product development phase in the therapeutics and diagnostics category per quarter. All units are in EUR and include only private companies

March, April 2016 financing rounds summary

Company Name	Sector	Amount (in Million EUR)	Ownership	Country
Novacyt	Biotechnology / R&D Services	6.9	Publicly listed on stock exchange	France
Enterome	Biotechnology - Therapeutics and Diagnostics	14.5	Private / independent	France
PeptiMimesis	Biotechnology - Therapeutics and Diagnostics	1.1	Private / independent	France
PB&B SA	Medical Technology	1.8	Private / independent	Switzerland
G-Therapeutics B.V.	Medical Technology	36.0	Private / independent	Netherlands
Cebiotex	Biotechnology / R&D Services	0.3	Private / independent	Spain
GeNeuro SA	Biotechnology - Therapeutics and Diagnostics	33.0	Publicly listed on stock exchange	Switzerland
iSTAR Medical SA	Medical Technology	10.0	Private / independent	Belgium
Keranova	Medical Technology	4.0	Private / independent	France
STAT-Diagnostica & Innovation S.L.	Medical Technology	25.0	Private / independent	Spain
MedDay Pharmaceuticals	Biotechnology - Therapeutics and Diagnostics	34.0	Private / independent	France
Thermosome GmbH.	Biotechnology - Therapeutics and Diagnostics	2.4	Private / independent	Germany
Thermosome GmbH.	Biotechnology - Therapeutics and Diagnostics	1.7	Private / independent	Germany
Metabomed Ltd.	Biotechnology - Therapeutics and Diagnostics	15.9	Private / independent	Israel
Anergis SA	Biotechnology - Therapeutics and Diagnostics	4.6	Private / independent	Switzerland
ValiRx plc	Biotechnology - Therapeutics and Diagnostics	0.6	Publicly listed on stock exchange	Belgium
Bluebee.	Biotechnology / R&D Services	10.0	Private / independent	Netherlands
Amal Therapeutics SA	Biotechnology - Therapeutics and Diagnostics	2.7	Private / independent	Switzerland
IDP Discovery Pharma SL	Biotechnology - Therapeutics and Diagnostics	0.2	Private / independent	Spain
GADETA B.V	Biotechnology - Therapeutics and Diagnostics	7.0	Private / independent	Netherlands



Gadeta BV	Biotechnology / R&D Services	7.0	Private / independent	Netherlands
Iterum Therapeutics Ltd.	Biotechnology - Therapeutics and Diagnostics	36.0	Private / independent	Ireland
Topas Therapeutics GmbH	Biotechnology - Therapeutics and Diagnostics	14.0	Private / independent	Germany
Peptomyc S.L	Biotechnology - Therapeutics and Diagnostics	0.5	Private / independent	Spain
ValiRx plc	Biotechnology - Therapeutics and Diagnostics	5.1	Publicly listed on stock exchange	Belgium
BerGenBio AS	Biotechnology - Therapeutics and Diagnostics	22.5	Private / independent	Norway
Gecko Biomedical	Medical Technology	22.9	Private / independent	France
eTheRNA NV	Biotechnology - Therapeutics and Diagnostics	24.0	Private / independent	Belgium
4Tech Cardio Ireland Ltd	Medical Technology	26.1	Private / independent	Ireland
Apra AB	Biotechnology - Therapeutics and Diagnostics	46.0	Private / independent	Sweden
Inbiomotion SL	Biotechnology - Therapeutics and Diagnostics	2.2	Private / independent	Spain
Labstyle Innovation	Medical Technology	UD	Publicly listed on stock exchange	Israel
Medasense Biometrics Ltd.	Medical Technology	7.2	Private / independent	Israel

UD: undisclosed

Source: Biotechgate - www.biotechgate.com



About this summary

The Life Sciences Financing Summary is published on a bi-monthly basis by Venture Valuation and Fit for Health 2.0 and can be downloaded for free either from our newsletter or from the website <http://www.fitforhealth.eu/>

The data used for this summary is taken from Venture Valuation's global Biotech and life science database Biotechgate. Biotechgate is a popular source for life sciences company and licensing deals information. If you are interested in learning more, please do not hesitate to contact us and to apply for a trial.

[Click here to learn more about Biotechgate »](#)

Venture Valuation
Kasernenstrasse 11
8004 Zurich
Switzerland

Phone: +41 (43) 321 86 60

Web: www.venturevaluation.com

Copyright © 2016 Venture Valuation VV Ltd. All rights reserved. This report is provided for information purposes only. All information regarding financing rounds, deal summaries and merger and acquisition transactions was obtained from company websites or industry newsletters including Fiercebitech, OnBioVC, and SECA. The above information can also be accessed on the Biotechgate website. All graphical information was provided via Biotechgate. While the information contained herein has been obtained from sources deemed reliable, Venture Valuation VV Ltd makes no guarantees that it is accurate, complete, timely, or sequential. For more information about Biotech companies, including deal, licensing and financing round details, please visit the Biotechgate website at www.biotechgate.com

Email: info@venturevaluation.com